Researchers delve into predictors of significant weight gain in pediatric patients on second-generation antipsychotics.
Development and predictors of clinically significant weight gain among pediatric patients prescribed second-generation antipsychotic medications have been investigated by researchers at the University of Houston College of Pharmacy (1✔ ✔Trusted Source
Trajectories and Predictors for the Development of Clinically Significant Weight Gain in Children and Adolescents Prescribed Second-Generation Antipsychotics
Go to source). The use of SGAs in pediatric patients has seen a notable increase over time, used to treat various psychiatric conditions, including attention-deficit hyperactivity disorder, autism spectrum disorder, and disruptive behavior disorders such as conduct disorder and oppositional defiant disorder.
‘Did You Know?
Antipsychotic medications are among the top-selling pharmaceutical drugs globally, with sales exceeding tens of billions of dollars annually.
#pediatric #weightgain #antipsychotics
’
While the SGAs have fewer side effects and increased performance than their first-generation counterparts, they do cause weight gain in 60% of children and adolescent patients taking them. “Our research indicates that preventing clinically significant weight gain may be possible,” said graduate researcher Ning Lyu in the Journal of Child and Adolescent Psychopharmacology.
“Using patient's characteristics at the initiation of SGA treatment could help clinicians in prescribing to certain patients.”
Unveiling Weight Gain Patterns
Lyu works under the supervision of Hua Chen, professor and assistant department chair of the Department of Pharmaceutical Health Outcomes and Policy at the UH College of Pharmacy.Lyu examined the records of over 16,000 pediatric patients aged 5 -19 from 2016 to 2021 and identified four distinctive weight-gain trajectories (1) Rapid (2) Gradual (3) Transit and (4) None.
Factors associated with a higher likelihood of having rapid or gradual CSWG versus nonsignificant weight gain were being younger (5–11 vs. 12–17), male, non-Hispanic white, with lower baseline body mass index scores.
Advertisement
“We also noted a range of demographic, clinical, and provider characteristics that distinguish between trajectory group membership.”
Advertisement
Reference:
- Trajectories and Predictors for the Development of Clinically Significant Weight Gain in Children and Adolescents Prescribed Second-Generation Antipsychotics - (https://pubmed.ncbi.nlm.nih.gov/38407930/)
Source-Eurekalert